Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit G. Pandya

Showing results (111-120 of 142) with videos related to

Pageof 15
Sort By:
Eclinicalmedicine|April 7, 2025
Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]Thierry Passeron, Khaled Ezzedine, Lltefat Hamzavi, et al.
Eclinicalmedicine|June 14, 2024
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyThierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
Trials|July 23, 2022
Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practiceNanja van Geel, Iltefat H Hamzavi, Amit G Pandya, et al.
Journal of the American Academy of Dermatology|April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring methodAmit G Pandya, Linda S Hynan, Rafia Bhore, et al.
Dermatology and Therapy|October 22, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDavid Rosmarin, Amit G Pandya, Thierry Passeron, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Therapeutic Advances in Chronic Disease|November 10, 2025
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
The British Journal of Dermatology|December 26, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 studyJohn E Harris, Kim Papp, Khaled Ezzedine, et al.
The British Journal of Dermatology|December 17, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 studyJohn E Harris, Kim Papp, Khaled Ezzedine, et al.
Pageof 15

Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
Eclinicalmedicine|April 7, 2025
Corrigendum to "Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study" [eClinicalMedicine 73(2024) 102655]Thierry Passeron, Khaled Ezzedine, Lltefat Hamzavi, et al.
Eclinicalmedicine|June 14, 2024
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging studyThierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, et al.
Skin Health and Disease|December 3, 2024
Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 yearsJohn E Harris, Amit G Pandya, Mark Lebwohl, et al.
Trials|July 23, 2022
Vitiligo International Task force for an Agreed List of core data (VITAL): study protocol of a vitiligo core outcome set (COS) and contextual factors for clinical trials, registries, and clinical practiceNanja van Geel, Iltefat H Hamzavi, Amit G Pandya, et al.
Journal of the American Academy of Dermatology|April 20, 2010
Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring methodAmit G Pandya, Linda S Hynan, Rafia Bhore, et al.
Dermatology and Therapy|October 22, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDavid Rosmarin, Amit G Pandya, Thierry Passeron, et al.
The New England Journal of Medicine|October 19, 2022
Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for VitiligoDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
Therapeutic Advances in Chronic Disease|November 10, 2025
Treatment of vitiligo with ruxolitinib cream in the TRuE-V1 and TRuE-V2 studies: a plain language summary of publicationDavid Rosmarin, Thierry Passeron, Amit G Pandya, et al.
The British Journal of Dermatology|December 26, 2025
Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 studyJohn E Harris, Kim Papp, Khaled Ezzedine, et al.
The British Journal of Dermatology|December 17, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 studyJohn E Harris, Kim Papp, Khaled Ezzedine, et al.
Pageof 15